Biologisk aldersvurdering hos voksne med Prader-Willi syndrom (ETABIOLPWS) (ETABIOLPWS)
Biologisk aldersvurdering hos voksne med Prader-Willi syndrom som gjennomgår et integrert multidisiplinært metabolsk rehabiliteringsprogram
The primary objective of the study is to compare, in a cohort of obese subjects with PWS hospitalized at the Division of Auxology, Istituto Auxologico Italiano, Piancavallo (VB), Italy, the age acceleration calculated at study entry (T0) with the age acceleration measured at the end of a 3-week multidisciplinary metabolic rehabilitation program (T1).
Secondary objectives are to correlate the biological age with the anthropometric characteristics (with particular reference to the body composition), the glycometabolic picture, the main parameters and cardiovascular risk factors, the therapy (previous and concomitant) with rhGH and the cognitive function (mainly, the IQ).
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Methods Thirty adults affected by clinically diagnosed and genetically confirmed PWS are recruited, regardless of the treatment (previous or concomitant) with rhGH (F/M = 15/15; age: ≥ 18 years; BMI > 35 kg/m2), hospitalized for a period of integrated multidisciplinary metabolic rehabilitation at the Division of Auxology, Istituto Auxologico Italiano, Piancavallo (VB), Italy.
After verifying the inclusion criteria, clinical and anthropometric data will be collected, including the evaluation of body composition with bioimpedance analysis. Cognitive function will be assessed with a psychometric scale (Wechsler Adult Intelligence Scale).
Blood samples will be taken from each patient upon admission to the hospital (T0) and after 3 weeks of rehabilitation hospitalization (at the same time to reduce circadian variability) for the determination of the basal glycometabolic profile (glucose, insulin, HOMA-IR, glycated Hb , triglycerides, total cholesterol, LDL, HDL, and hsPCR), as well as circulating levels of leptin, IL-6, and TNF-α.
The samples taken will be used for DNA extraction. DNA methylation will be performed by treatment with sodium bisulphite and PCR-Pyrosequencing.
Biological age measurement Biological (epigenetic) age will be measured using the two algorithms of Zbiec-Piekarska (9) and Daunay (10), based on the level of DNA methylation in specific gene loci. To have an estimate of the epigenetic (biological) age that is independent of the chronological age, we will use a measure defined as age acceleration, from which, with statistical inference, we will calculate the age acceleration. To calculate it, a linear regression model with the chronological age as the independent variable and the epigenetic age as the dependent variable will be applied; the difference between the observed value and the one predicted by the model will constitute the age acceleration due to epigenetic effects. In the event that the epigenetic age is greater than the chronological age, the age acceleration will have a positive value expressed in years, negative if vice versa.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
Verbania
-
Oggebbio, Verbania, Italia, 28824
- Istituto Auxologico Italiano IRCCS, Site Piancavallo
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Adult patients with Prader-Willi syndrome with BMI > 35 kg/m2
Beskrivelse
Inclusion Criteria:
- adult patients with PWS, clinically diagnosed and genetically confirmed, regardless of rhGH treatment (previous or concomitant)
- age: ≥ 18 years
- BMI > 35 kg/m2
- hospitalization for integrated multidisciplinary metabolic rehabilitation program
Exclusion Criteria:
- age < 18 years
- BMI < 35 kg/m2
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
DNA methylation
Tidsramme: Baseline and at the end of the rehabilitation program (21 days)
|
Change in level of DNA methylation |
Baseline and at the end of the rehabilitation program (21 days)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Glycometabolic profile: glucose
Tidsramme: Baseline and at the end of the rehabilitation program (21 days)
|
Change in glycometabolic profile - glucose levels |
Baseline and at the end of the rehabilitation program (21 days)
|
|
Glycometabolic profile: insulin
Tidsramme: Baseline and at the end of the rehabilitation program (21 days)
|
Change in glycometabolic profile - insulin levels |
Baseline and at the end of the rehabilitation program (21 days)
|
|
Body fat mass
Tidsramme: Baseline and at the end of the rehabilitation program (21 days)
|
Change in body fat mass - bioimpedance analysis |
Baseline and at the end of the rehabilitation program (21 days)
|
|
Body fat free mass
Tidsramme: Baseline and at the end of the rehabilitation program (21 days)
|
Change in body fat free mass - bioimpedance analysis |
Baseline and at the end of the rehabilitation program (21 days)
|
|
Body weight
Tidsramme: Baseline and at the end of the rehabilitation program (21 days)
|
Change in body weight |
Baseline and at the end of the rehabilitation program (21 days)
|
|
Body mass index
Tidsramme: Baseline and at the end of the rehabilitation program (21 days)
|
Change in body mass index |
Baseline and at the end of the rehabilitation program (21 days)
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Avtrykksforstyrrelser
- Nevrologiske manifestasjoner
- Sykdommer i nervesystemet
- Ernæringsforstyrrelser
- Genetiske sykdommer, medfødte
- Overernæring
- Kroppsvekt
- Nevroatferdsmanifestasjoner
- Medfødte abnormiteter
- Abnormiteter, flere
- Overvektig
- Intellektuell funksjonshemming
- Kromosomforstyrrelser
- Medfødte, arvelige og neonatale sykdommer og abnormiteter
- Patologiske tilstander, tegn og symptomer
- Ernæringsmessige og metabolske sykdommer
- Tegn og symptomer
- Overvekt
- Prader-Willi syndrom
Andre studie-ID-numre
- 01C213
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .